Brokers name 3 ASX shares to buy right now

Brokers have named Harvey Norman Holdings Limited (ASX:HVN) and these ASX shares as buys this week. Here's why they are bullish…

| More on:
sign containing the words buy now, asx growth shares ANZ Bank broker upgrade

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Australia's top brokers have been busy adjusting their estimates and recommendations again, leading to the release of a large number of broker notes this week.

Three broker buy ratings that have caught my eye are summarised below. Here's why brokers think these ASX shares are in the buy zone:

Harvey Norman Holdings Limited (ASX: HVN)

According to a note out of Citi, its analysts have retained their buy rating and lifted the price target on this retailer's shares to $4.50. The broker was pleasantly surprised with Harvey Norman's sales growth during April and May. And while it isn't clear whether its bottom line is growing as strongly, Citi appears confident that the company will deliver a solid full year result in August. I agree with Citi and feel Harvey Norman could be a decent option.

Newcrest Mining Limited (ASX: NCM)

Analysts at UBS have retained their buy rating and $35.00 price target on this gold miner's shares. This follows the release of drilling results from Red Chris and Havieron this week. UBS was pleased with the results from Havieron and believes they are strong enough for management to seriously consider mining the orebody. It doesn't feel this potential has been priced into its shares. I think UBS makes some good points and Newcrest could be worth considering if you're looking for exposure to gold.

Opthea Ltd (ASX: OPT)

A note out of Goldman Sachs reveals that its analysts have retained their conviction buy rating and $5.20 price target on this biotech company's shares. This follows the release of data from its study evaluating OPT-302 in the treatment of Diabetic Macular Edema. Goldman notes that the data was unconvincing and has raised more questions than answers. Nevertheless, the broker believes the near-term story remains broadly unchanged. This is because OPT-302 has already demonstrated a statistically significant benefit in a larger trial for Wet Age-Related Macular Degeneration. This has a significant market opportunity. I agree with Goldman Sachs and think Opthea could be a top long term option.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

White declining arrow on a blue graph with an animated man representing a falling share price.
Materials Shares

Experts call time on these rip-snorting ASX 200 mining shares

These 2 ASX 200 mining stocks have risen by 160% and 230%, respectively, over the past 12 months.

Read more »

man and woman calculating financial assests
Share Market News

DroneShield hits $200m milestone as 9.2m options vest and 2025 expense revealed

DroneShield reached a $200m milestone, vesting 9.2m employee options and booking a $23.5m non-cash expense in 2025.

Read more »

growth in housing asx shares represented by little wooden houses next to rising red arrow
Share Market News

Shares vs. property: Which delivered the best capital growth in 2025?

We compare the capital growth of ASX 200 shares to Australia's metro and regional property markets.

Read more »

A man cheers after winning computer game while woman sitting next to him looks upset.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy end to the trading week today.

Read more »

Three business people stand on platforms in the desert and look out through telescopes.
Best Shares

1 ASX dividend share set to excel long term, even while down 13%

Good quality shares don't often sell off at this margin.

Read more »

Two people comparing and analysing material.
Broker Notes

Buy, hold, sell: Netwealth, Santos, and South32 shares

Morgans has given its verdict on these shares following updates.

Read more »

Emotional euphoric young woman giving high five to male partner, celebrating family achievement, getting bank loan approval, or financial or investing success.
Share Gainers

Why Life360, Northern Star, Objective Corp, and Rox shares are charging higher today

These shares are having a strong finish to the week. But why?

Read more »

A woman sits on sofa pondering a question.
Share Market News

Insignia Financial responds to ASX on disclosure and governance

Insignia Financial updates shareholders on ASX compliance and new governance controls around performance rights disclosure.

Read more »